

Michael Boe Mller

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8158475/michael-boe-moller-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers

5,795
citations

40
h-index

72
g-index

184
ext. papers

6,636
ext. citations

4.2
avg, IF

5.07
L-index

#	Paper	IF	Citations
162	Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3460-7	2.2	494
161	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013 , 121, 4021-31;	2.2	473
160	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Leukemia</i> , 2013 , 27, 2103-13	10.7	251
159	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012 , 120, 3986-96	2.2	223
158	Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. <i>American Journal of Pathology</i> , 1999 , 155, 1879-84	5.8	209
157	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013 , 121, 2715-24	2.2	157
156	Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases. <i>British Journal of Haematology</i> , 2004 , 124, 151-9	4.5	156
155	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008 , 112, 3088-98	2.2	138
154	Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. <i>Journal of Molecular Diagnostics</i> , 2011 , 13, 180-8	5.1	126
153	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013 , 98, 255-63	6.6	125
152	High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 612-9	6.7	111
151	The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. <i>European Journal of Haematology</i> , 2007 , 79, 508-15	3.8	108
150	Epidemiology of systemic mastocytosis in Denmark. <i>British Journal of Haematology</i> , 2014 , 166, 521-8	4.5	104
149	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014 , 27, 958-71	9.8	99
148	Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. The Danish Lymphoma Study Group, LYFO. <i>European Journal of Cancer</i> , 1994 , 30A, 1760-4	7.5	98
147	Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. <i>Clinical Cancer Research</i> , 2014 , 20, 2338-49	12.9	96
146	Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1379-88	2.2	73

145	Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. <i>American Journal of Hematology</i> , 2014 , 89, 493-8	7.1	72
144	Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. <i>Leukemia Research</i> , 2013 , 37, 1041-5	2.7	72
143	Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. <i>Blood</i> , 2011 , 117, 6638-49	2.2	71
142	Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. <i>Leukemia</i> , 1999 , 13, 453-9	10.7	71
141	and rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. <i>Blood</i> , 2017 , 130, 554-557	2.2	68
140	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016 , 7, 2401-16	3.3	68
139	Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. <i>Leukemia</i> , 2000 , 14, 1727-35	10.7	67
138	Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. <i>Hematology</i> , 2009 , 14, 331-4	2.2	65
137	P27 in cell cycle control and cancer. <i>Leukemia and Lymphoma</i> , 2000 , 39, 19-27	1.9	58
136	Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015 , 6, 5615-33	3.3	54
135	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015 , 6, 5597-614	3.3	53
134	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019 , 7, 644-657	12.5	52
133	Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , 2014 , 20, 5113-23	12.9	52
132	Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. <i>Leukemia</i> , 2000 , 14, 898-904	10.7	51
131	R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. <i>Annals of Oncology</i> , 2012 , 23, 147-153	10.3	46
130	Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis. <i>European Journal of Haematology</i> , 2013 , 91, 106-11	3.8	45
129	Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 135, 262-4	11.5	44
128	FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. <i>Leukemia</i> , 2016 , 30, 605-16	10.7	44

127	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with rearrangements. <i>Blood</i> , 2018 , 132, 1386-1398	2.2	44
126	Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. <i>European Journal of Haematology</i> , 2007 , 79, 501-7	3.8	43
125	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013 , 122, 2630-40	2.2	41
124	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016 , 128, 3083-3100	2.2	41
123	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015 , 28, 1555-73	9.8	40
122	Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. <i>American Journal of Hematology</i> , 2016 , 91, 1069-1075	7.1	40
121	Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016 , 22, 3593-605	12.9	39
120	Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. <i>European Journal of Haematology</i> , 2012 , 89, 42-6	3.8	38
119	Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. <i>Leukemia</i> , 2008 , 22, 194-5	10.7	38
118	Microarray-based classification of diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2005 , 74, 453-65	3.8	38
117	KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013 , 132, 723-728	11.5	36
116	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013 , 121, 4529-40	2.2	35
115	Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. <i>Annals of Hematology</i> , 2008 , 87, 847-50	3	35
114	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017 , 187, 1700-1716	5.8	34
113	Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features. <i>American Journal of Clinical Pathology</i> , 2001 , 115, 404-12	1.9	32
112	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015 , 6, 23157-80	3.3	32
111	High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma. <i>Histopathology</i> , 2014 , 65, 490-500	7.3	31
110	Prognostic significance of metallothionein in B-cell lymphomas. <i>Blood</i> , 2006 , 108, 3514-9	2.2	31

109	Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2015 , 26, 393-9	10.3	30
108	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018 , 20, 574-593	6.4	30
107	NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. <i>European Journal of Haematology</i> , 2011 , 87, 400-8	3.8	30
106	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?. <i>Oncotarget</i> , 2015 , 6, 13933-45	3.3	29
105	TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma. <i>Histopathology</i> , 2017 , 71, 98-111	7.3	28
104	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , 2014 , 120, 1818-29	6.4	28
103	Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease. <i>Leukemia and Lymphoma</i> , 2014 , 55, 911-9	1.9	27
102	Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. <i>Histopathology</i> , 2002 , 41, 322-30	7.3	27
101	Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1677-85	1.9	26
100	Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. <i>Journal of Internal Medicine</i> , 2015 , 278, 323-32	10.8	26
99	Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. <i>Leukemia</i> , 2014 , 28, 362-72	10.7	24
98	Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. <i>European Journal of Haematology</i> , 2016 , 96, 46-54	3.8	23
97	Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 130, 806-8	11.5	22
96	Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. <i>Hematology</i> , 2009 , 14, 11-5.2	5.2	22
95	Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. <i>British Journal of Haematology</i> , 2006 , 133, 43-9	4.5	22
94	Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1. <i>British Journal of Haematology</i> , 1999 , 105, 730-6	4.5	22
93	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019 , 32, 741-754	9.8	20
92	Conditional survival of patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2006 , 106, 2165-70	6.4	20

91	RelA NF- κ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016 , 8, 3321-3340	5.6	20
90	Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?. <i>Oncotarget</i> , 2014 , 5, 1912-25	3.3	19
89	A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2556-62	1.9	18
88	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015 , 28, 1297-314	9.8	18
87	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016 , 8, 345-65	5.6	17
86	High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2015 , 39, 555-60	2.7	16
85	Evaluation of NF- κ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015 , 28, 1202-13	9.8	15
84	Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort. <i>Apmis</i> , 2015 , 123, 652-8	3.4	15
83	Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. <i>British Journal of Haematology</i> , 2013 , 161, 373-82	4.5	14
82	Development and blind clinical validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL. <i>PLoS ONE</i> , 2015 , 10, e0115538	3.7	14
81	Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. <i>Journal of Clinical Pathology</i> , 2013 , 66, 956-61	3.9	14
80	Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study. <i>Transplant International</i> , 2016 , 29, 483-93	3	14
79	NF- κ B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. <i>Modern Pathology</i> , 2017 , 30, 854-876	9.8	13
78	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBfit). <i>Cancer Medicine</i> , 2018 , 7, 4447-4455	4.8	13
77	Clinical relevance of sensitive and quantitative STAT3 mutation analysis using next-generation sequencing in T-cell large granular lymphocytic leukemia. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 382-92	5.1	13
76	FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. <i>Oncotarget</i> , 2016 , 7, 52940-52956	3.3	13
75	DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. <i>Pathology</i> , 2017 , 49, 731-739	1.6	12
74	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies 2019 , 7, 272		12

73	Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Experimental and Molecular Pathology</i> , 2015 , 99, 537-45	4.4	12
72	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 148	22.4	12
71	Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. <i>Haematologica</i> , 2020 , 105, 2432-2439	6.6	12
70	Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. <i>Hematological Oncology</i> , 2015 , 33, 120-8	1.3	12
69	LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations. <i>European Journal of Haematology</i> , 2016 , 97, 175-82	3.8	12
68	Validation of putative reference genes for normalization of Q-RT-PCR data from paraffin-embedded lymphoid tissue. <i>Diagnostic Molecular Pathology</i> , 2009 , 18, 243-9		11
67	High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. <i>Hematology</i> , 2008 , 13, 71-6	2.2	11
66	Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. <i>Acta Dermato-Venereologica</i> , 2016 , 96, 602-12	2.2	11
65	Systemic mastocytosis--a systematic review. <i>Danish Medical Journal</i> , 2012 , 59, A4397	3.8	11
64	Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma. <i>European Journal of Haematology</i> , 2018 , 101, 585	3.8	10
63	Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate. <i>Pediatric Blood and Cancer</i> , 2010 , 55, 730-2	3	10
62	Molecular control of the cell cycle in cancer: biological and clinical aspects. <i>Danish Medical Bulletin</i> , 2003 , 50, 118-38		10
61	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <i>British Journal of Cancer</i> , 2017 , 117, 1685-1688	8.7	9
60	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021 , 19, 249-260	6.6	9
59	Successful management of transfusion-dependent congenital dyserythropoietic anemia type 1b with interferon alfa-2a. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26866	3	8
58	Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1824-36	8.8	8
57	Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis. <i>European Journal of Haematology</i> , 2016 , 96, 381-8	3.8	8
56	Pediatric Expression of Mast Cell Activation Disorders. <i>Immunology and Allergy Clinics of North America</i> , 2018 , 38, 365-377	3.3	8

55	KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis. <i>Dermatology</i> , 2013 , 226, 233-7	4.4	8
54	Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>British Journal of Haematology</i> , 2016 , 174, 876-86	4.5	7
53	Relationship of intratumoural protein expression patterns to age and Epstein-Barr virus status in classical Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2015 , 95, 137-49	3.8	6
52	Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1338-44	1.9	6
51	Prognosis of localized diffuse large B-cell lymphoma in younger patients. <i>Cancer</i> , 2003 , 98, 516-21	6.4	6
50	Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2003 , 74, 94-8	7.1	6
49	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. <i>American Journal of Human Genetics</i> , 2021 , 108, 284-294	11	6
48	Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment. <i>Epigenomics</i> , 2018 , 10, 1155-1166	4.4	6
47	Comparison of gDNA-based versus mRNA-based KIT D816V mutation analysis reveals large differences between blood and bone marrow in systemic mastocytosis. <i>British Journal of Haematology</i> , 2017 , 178, 330-332	4.5	5
46	Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage. <i>Apmis</i> , 2007 , 115, 778-83	3.4	5
45	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020 , 4, 3391-3404	7.8	5
44	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021 , 5, 2481-2489	7.8	5
43	Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified. <i>Blood Advances</i> , 2018 , 2, 2533-2542	7.8	5
42	Clinical validation of a new commercial highly sensitive KIT D816V mutation analysis in mastocytosis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1489-1491	9.3	4
41	Infantile hemophagocytic lymphohistiocytosis in a case of chediak-higashi syndrome caused by a mutation in the LYST/CHS1 gene presenting with delayed umbilical cord detachment and diarrhea. <i>Journal of Pediatric Hematology/Oncology</i> , 2015 , 37, e73-9	1.2	3
40	HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort. <i>Transplantation Direct</i> , 2015 , 1, e25	2.3	3
39	High intratumoural galectin-1 expression predicts adverse outcome in ALK ALCL and CD30 PTCL-NOS. <i>Hematological Oncology</i> , 2020 , 38, 59-66	1.3	3
38	A child with mastocytosis and lymphomatoid papulosis. <i>Clinical Case Reports (discontinued)</i> , 2016 , 4, 517-9.7		3

37	Towards rational diagnostics in mastocytosis: clinical validation of sensitive KIT D816V mutation analysis of unfractionated whole-blood. <i>Leukemia and Lymphoma</i> , 2019 , 60, 268-270	1.9	2
36	Relapse of myeloid neoplasm with eosinophilia and PDGFRA rearrangement after imatinib discontinuation in a pediatric patient. <i>Pediatric Blood and Cancer</i> , 2014 , 61, 2328	3	2
35	Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia. <i>Apmis</i> , 2007 , 115, 1267-73	3.4	2
34	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2011 , 118, 949-949	2.2	2
33	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, e19-e25	2.5	2
32	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. <i>OncImmunity</i> , 2021 , 10, 1928365	7.2	2
31	Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma. <i>Aids</i> , 2017 , 31, 2311-2313	3.5	1
30	Venom anaphylaxis can mimic other serious conditions and disclose important underlying disease. <i>Annals of Allergy, Asthma and Immunology</i> , 2018 , 120, 338-339	3.2	1
29	Differential protein expression of peroxiredoxin-1 in classical Hodgkin Lymphoma: a possible correlation to clinical behaviour. <i>Hematological Oncology</i> , 2015 , 33, 253-5	1.3	1
28	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.. <i>Blood Cancer Journal</i> , 2022 , 12, 25	7	1
27	Primary thymic extranodal marginal zone B cell lymphoma as an incidental finding in a Caucasian woman. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	1
26	MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. <i>Blood</i> , 2019 , 134, 5092-5092	2.2	1
25	Minimal Residual Disease and Normalization of the Bone Marrow after Long-Term Treatment with Alpha-Interferon2b in Polycythemia Vera. A Report on Seven Patients in Sustained Complete Hematological Remission with Major Molecular Responses.. <i>Blood</i> , 2008 , 112, 1744-1744	2.2	1
24	Poor Survival Predicted by MDM2 Oncoprotein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Wild-Type TP53 Gene. <i>Blood</i> , 2008 , 112, 5269-5269	2.2	1
23	miR34s in Normal and Malignant B-Cells: miR34A Plays a Dominant Role in Normal B-Cells, and aggressive Diffuse Large B-Cell Lymphoma Carry Combined Lesions of TP53, MIR34A, and MIR34B/C. <i>Blood</i> , 2012 , 120, 296-296	2.2	1
22	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012 , 120, 544-544	2.2	1
21	Tumor Microenvironmental Features and Outcome in Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2014 , 124, 1617-1617	2.2	1
20	Limited Efficacy of Hydroxyurea in Lowering of the JAK2 V617F Allele Burden.. <i>Blood</i> , 2008 , 112, 1750-1750	1.5	1

19	Diffuse Large B-Cell Lymphoma With Combined TP53 mutation and MIR34A methylation: Another Double hit Lymphoma With Very Poor Outcome?. <i>Blood</i> , 2013 , 122, 83-83	2.2	1
18	-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than mutation load. <i>Haematologica</i> , 2021 ,	6.6	1
17	Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4. <i>Scientific Reports</i> , 2021 , 11, 19092	4.9	1
16	Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma. <i>Leukemia Research Reports</i> , 2021 , 15, 100255	0.6	0
15	Intratumoral expression of CD38 in patients with post-transplant lymphoproliferative disorder. <i>Acta Oncologica</i> , 2021 , 60, 1637-1642	3.2	0
14	Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma. <i>Leukemia Research</i> , 2019 , 78, 1-2	2.7	
13	A5.27 Ro52 Expression is a Prognostic Factor for Survival in B Cell Lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A40.2-A40	2.4	
12	CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus.. <i>Leukemia and Lymphoma</i> , 2022 , 1-5	1.9	
11	Structural Profiles of p53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study.. <i>Blood</i> , 2006 , 108, 811-811	2.2	
10	Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 1499-1499	2.2	
9	NF- κ B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014 , 124, 1620-1620	2.2	
8	Proteomic Analysis Identifies Outcome-Predictive Clusters in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified. <i>Blood</i> , 2014 , 124, 1623-1623	2.2	
7	Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014 , 124, 143-143	2.2	
6	A Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes with Prognosis. <i>Blood</i> , 2014 , 124, 2973-2973	2.2	
5	Mutation in the Nucleophosmin Gene (NPM1) Is a Stable Marker for Minimal Residual Disease Monitoring in Acute Myeloid Leukemia Patients with Increased Sensitivity and Specificity Compared to Expression of the Wilms Tumor (WT1) Gene.. <i>Blood</i> , 2009 , 114, 1602-1602	2.2	
4	A New Simplified Prognostic Index with Age Cut-off of 70 Years for Patients with Diffuse Large B-Cell Lymphoma. A Population-Based Analysis From the Danish Lymphoma Registry, LYFO. <i>Blood</i> , 2012 , 120, 3651-3651	2.2	
3	miRNA Profiling Predicts Survival and Identifies a Novel Putative Oncomir in Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy. <i>Blood</i> , 2012 , 120, 1548-1548	2.2	
2	Diagnosis, treatment, and outcome of primary CNS lymphoma-a single-center experience.. <i>Acta Neurochirurgica</i> , 2022 , 1	3	

- 1 Myeloid sarcoma developing in pre-existing pyoderma gangrenosum. *Acta Dermato-Venereologica*, **2009**, 89, 175-7 2.2